Back to top

Analyst Blog

On Apr 8, Zacks Investment Research upgraded Alere inc. (ALR - Snapshot Report) to a Zacks Rank #3 (Hold) from a Zacks Rank #4 (Sell).

Why the Upgrade?

The long-term expected earnings growth rate for this Massachusetts-based medical products stock is 12.5%. Moreover, Alere has delivered positive earnings surprises in all of the last 4 quarters with an average beat of 27.6%.

Alere reported its fourth-quarter results on Feb 6, 2014. Adjusted earnings per share came in at 62 cents, exceeding the Zacks Consensus Estimate of 56 cents by 10.7% and the prior-year earnings by 26.5%.

Earnings were primarily aided by healthy top-line growth of 2.2% in the reported quarter, which was primarily driven by a 2% increase in net revenues from the Professional Diagnostics business.

With respect to segment performance, net product revenues from Alere's Infectious Disease business increased 6.4%, principally driven by growth in HIV and malaria revenues.

In the second half of 2013, Alere's U.S. flu sales increased impressively by 19.3% year over year, reflecting the company's strong positioning with the distributors in both the hospital and physician's office market segments. Banking on its successful track record, Alere is anticipating consistent improvement in its business in 2014 and beyond.

The Zacks Consensus Estimate for earnings for 2014 remained flat at $2.47 per share with no downward revision over the last 30 days. For 2015, no estimates were revised downward over the same time frame, keeping the Zacks Consensus Estimate unchanged at $2.79 per share.

Other Stocks to Consider

In the medical products space, Enzymotec Ltd. (ENZY - Snapshot Report), Covidien plc (COV) and William Demant Holding A/S (WILYY) are performing well. While Enzymotec holds a Zacks Rank #1 (Strong Buy), both Covidien and William Demant retain a Zacks Rank #2 (Buy).

Read the Full Research Report on ALR
Read the Full Research Report on ENZY
Read the Full Research Report on WILYY

Zacks Investment Research

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%